Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis

Gemme Campbell-Salome; Laney K. Jones; Max F. Masnick; Nephi A. Walton; Catherine D. Ahmed; Adam H. Buchanan; Andrew Brangan; Edward D. Esplin; David G. Kann; Ilene G. Ladd; Melissa A. Kelly; Iris Kindt; H. Lester Kirchner; Mary P. McGowan; Megan N. McMinn; Ana Morales; Kelly D. Myers; Matthew T. Oetjens; Alanna Kulchak Rahm; Tara J. Schmidlen; Amanda Sheldon; Emilie Simmons; Moran Snir; Natasha T. Strande; Nicole L. Walters; Katherine Wilemon; Marc S. Williams; Samuel S. Gidding; Amy C. Sturm

Journal ArticleOPEN ACCESS

Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis

Campbell-Salome G
Jones L
Masnick M
et al.

Circulation: Genomic and Precision Medicine (2021) 14(1)

DOI: 10.1161/circgen.120.003120

N/ACitations

4Readers

Abstract

Background: Familial hypercholesterolemia (FH) is the most common cardiovascular genetic disorder and, if left untreated, is associated with increased risk of premature atherosclerotic cardiovascul...

Cite

CITATION STYLE

APA

Campbell-Salome, G., Jones, L. K., Masnick, M. F., Walton, N. A., Ahmed, C. D., Buchanan, A. H., … Sturm, A. C. (2021). Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis. Circulation: Genomic and Precision Medicine, 14(1). https://doi.org/10.1161/circgen.120.003120

Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis

Abstract

Cite

Register to see more suggestions